Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Filing today

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Nov 05, 2023 10:03pm

152 Views

Post# 35718696

RE:New Filing today

I scanned it. Looks like the totality of all changes over 5 separate amendments and what was presented before. I'm assuming they know they aren't going to be able to meet the trailing 12 month EBITDA (LTM EBITDA) requirements and the associated higher cash balances without raising the additional capital. Or, they truly did only raise the additional capital to save their jobs. Either way, we have been completely misled. There's zero accountability.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023